Novo Nordisk: Obesity war heating up, but Danish giant can still be a winner

Novo Nordisk is experiencing significant market share erosion in Europe's weekly GLP-1 injection market, with its share falling to 53% in May from 68% in February 2024, as Eli Lilly's Mounjaro gains traction in key markets like Germany and the UK with higher-priced offerings. Despite this revenue impact, Morgan Stanley has raised Novo's price target to DKr550, signaling confidence in a recovery driven by easing supply constraints and accelerating new product launches, projecting 14% sales growth and 17% operating profit growth for the year.

Analysis

Novo Nordisk (NVO) is facing intensified competition in the European GLP-1 market, as evidenced by a significant erosion of its market share from 68% in February 2024 to 53% in May. This decline is directly attributable to the successful commercial execution and product differentiation of Eli Lilly's (LLY) Mounjaro, which has surpassed Novo's offerings to become the top seller in key markets like Germany and the UK. The shift towards higher-priced drugs like Mounjaro is directly impacting Novo's revenue streams. Despite these competitive pressures, Morgan Stanley has issued a bullish revision, raising its price target on NVO to DKr550 from DKr441.20. This optimism is predicated on expectations of easing supply constraints, supported by a recent rebound in Ozempic availability, and accelerating product rollouts in new markets such as France and Italy. The bank forecasts robust fundamentals for Novo, projecting 14% sales growth and 17% operating profit growth for the current year, suggesting a strong potential for recovery even as the competitive landscape heats up.

Key Decisions for Investors

• Investors should weigh Novo Nordisk's current market share erosion against Morgan Stanley's optimistic growth forecasts of 14% in sales and 17% in operating profit, which are contingent on supply issues easing.
• Monitor the competitive dynamics closely, as Eli Lilly's success is attributed to fundamental product differentiation and execution, indicating a sustained challenge rather than a temporary disruption.
• Given the stock is trading at DKr440.70, well below the new DKr550 price target, investors might consider whether the current valuation adequately discounts the competitive risks relative to the analyst-projected recovery.
• Pay close attention to the uptake and market penetration of Wegovy in France and Italy, as performance in these new markets will be a critical indicator of Novo's ability to achieve its growth targets.